Please login to the form below

Not currently logged in

HER-2 breast cancer

This page shows the latest HER-2 breast cancer news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca's Enhertu receives FDA grant for priority review

AstraZeneca's Enhertu receives FDA grant for priority review

The approval is based on results from the DESTINY-Breast03 trial which showed a significant risk reduction of unresectable or metastatic HER-2 positive breast cancer progression. ... For patients diagnosed with HER2-positive metastatic breast cancer,

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Putting the ovation into innovation: trends from ESMO Putting the ovation into innovation: trends from ESMO

    The real value of real-world evidence in advanced breast cancer. Real-world evidence (RWE) is playing an ever- increasing role in treatment decision-making, in all forms of cancer. ... the ESMO 2020 Congress combination with endocrine therapy and

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... in breast and gastric cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts


Add my company
Anthem PR

With a rare strength in media and influencer relations, Anthem’s award-winning team offers a fresh approach to health PR...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...